Tag Archive: inserm

  1. World AIDS DAY Part 1: EAVI2020’s research to a better future | Trial EAVI2020_3Sm

    Leave a Comment

    Hi! I’m the EAVI2020-3Sm trial and I am testing the VAC02 vaccine. VAC02 is an HIV vaccine candidate based on discovery of the immunogenicity of a conserved gp41 peptide, namely W614A-3S, recognized by natural broadly Neutralizing Ab detected in HIV-1 infected individuals. It is composed of gp41-3Sm peptide that is coupled to CRM197 in an adjuvant formulation. VAC02 is an HIV vaccine candidate based on discovery of the immunogenicity of a conserved gp41 peptide, namely W614A-3S, recognized by natural broadly neutralizing Ab detected in HIV-1 infected individuals. It is composed of gp41-3Sm peptide that is coupled to CRM197 in an adjuvant formulation. The first in man clinical trial will discern the safety and the immunogenicity of VAC02 as well as the induction of broadly neutralizing antibodies against HIV-1.

    Let me introduce you the team: Robin Shattock (Imperial College London, Study sponsor, UK), Behazine Combadiere, Vincent Vieillard and Patrice Debre (Institut National de Santé et de Recherche Medicale – Inserm, Cimi-Paris, France), Agence Nationale de Recherche sur le SIDA et Maladies Infectieuses Emergentes (ANRS-MIE, France) and Minka Therapeutics (France), they all work together to ensure I am successful!

    Progress has been made in epitope identification for the induction of broadly neutralizing antibodies. Peptide-based vaccination has become one of the challenges of this decade. Based on the discovery of natural broadly neutralizing antibodies against a conserved short epitope of GP41 in long-term non progressor HIV+ patients however rarely observed in HIV progressors, the EAVI2020-3Sm trial will be pioneering in the induction of such antibodies against HIV in man using VAC02 designed vaccine. Furthermore, the translation of VAC02 vaccine candidate into an experimental medicine (EM) study with results expected in 2022 will accelerate progress in the development of an HIV-1 vaccine.

    Find out more about the other EAVI2020 trials taking place:

    info card on clinical trial HIV-CORE 0051

    HIV-CORE 0051

    info card on clinical trial HIV-CORE 0052

    HIV-CORE 0052

    info card on clinical trial EAVI2020_01


    info card on clinical trial BCN03


    Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

    To donate and show your support, go to the National AIDS Trust website

    For World AIDS Day 2022, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

    It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

  2. EAVI2020 partner focused stories: INSERM

    Leave a Comment

    The Center for Immunology and Microbial Infection (CIMI-Paris) is a research unit of Inserm – Institut National de Santé et de Recherche Médicale (French National Institutes of Health).

    At CIMI-Paris and within the EAVI2020 program Behazine Combadière (Director of research, Inserm), Vincent Vieillard (Director of research, CNRS) and Patrice Debré (Professor, Pitié-Salpêtrière Hospital) will be looking at mechanism of immunogenicity and biomarkers of vaccine efficacy to accelerate identification of novel HIV vaccine candidates.

    Behazine Combadiere‘s Immunity and vaccination Lab

    The Immunity and vaccination Lab is trying to improve current methods of vaccination against infectious diseases. Previous to EAVI2020, Behazine Combadiere coordinated the CUT’HIVAC consortium, highly involved in the field of HIV vaccination in FP7, which lead to the implantation of 4 HIV vaccine clinical trials in collaboration with ICL (UK), Irsicaixa (Spain) and Impacta (Perou).

    We have a special interest in modulating innate immunity to shape the right quality of adaptive immunity by studying different vaccine formulations, adjuvants and routes of administration. The major achievement of the team is the development of skin vaccination methods from bench to clinical development (Trancutaneous vaccination, J Invest Derm 2006, J. Immunol. 2008, PlosOne 2010) as well as the study of early innate inflammatory processes (J Immunol cutting edge 2012, Immunity 2012, Nat Com 2015). To improve vaccination strategies, we seek to understand all the cellular and molecular mechanisms involved in the immune response to vaccines, adjuvants and against viral infections (J Exp. Med. 2004, J. Clin. Invest. 2010, J Immunol 2013 J. Clin. Invest. 2014). Our project integrates basic research, and the transfer of knowledge to clinical trials in humans.

    Dissection by systems biology approaches

    Our participation in EAVI2020 is to dissect by systems biology approaches, early biomarkers of vaccine efficacy against HIV in humans. Dissection of early innate cellular and molecular biomarkers will help in prediction of vaccine efficacy and amelioration of vaccination strategies for a safe and efficient HIV vaccine.

    Vincent Vieillard’s NK cells and pathologies Lab

    In the last decade, the NK cells and pathologies lab has developed a new vaccine strategy based on a highly specific and conserved motif of the gp41 HIV-1 protein, called 3S (Proc Natl Acad USA 2005). This motif induces the expression of NKp44L, the cellular ligand of an activating NK receptor (NKp44) (Blood 2013), rendering CD4+ T cells sensitive to NK lysis. NKp44L expression is strongly correlated with both the decline of CD4 cell count, and other side effects (OncoTarget 2016). A 3S vaccine strategy was tested in SHIV-infected macaques (Proc Natl Acad USA 2008, Vaccine 2012), and still in progress in clinical trials. More recently, we generated an adapted-3S peptide, called W614A-3S, able to elicit neutralizing antibodies in different animal models (Clin Infect Dis 2013, Personal data).

    Testing of different vaccine formulations

    Our participation in EAVI2020 is to test different vaccine formulations, based on the W614A-3S peptide, to favor the highest level of broadly neutralizing activity. The ultimate goal is to obtain an in vivo proof-of-concept in a non-human primate model of HIV infection, before starting a first-in-human study.